Dataset Information
Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy.
Ontology highlight
ABSTRACT: Background
Transwomen have an increased risk of HIV acquisition compared with other adults. Drug-drug interactions between pre-exposure prophylaxis (PrEP) and gender-affirming therapy are cited as a reason for poor PrEP uptake among transwomen. We evaluated plasma tenofovir and emtricitabine pharmacokinetics and their active intracellular anabolites, tenofovir-diphosphate and emtricitabine-triphosphate, in transwomen receiving feminizing hormones.Methods
We enrolled HIV-negative transwomen (?19?years) not receiving PrEP. Participants took oral tenofovir disoproxil fumarate/emtricitabine 300/200?mg daily for 14?days. Plasma was collected at 0?h (pre-dose), 0.5, 1, 2, 3, 4, 6, 8 and 12?h on day 14 post-tenofovir disoproxil fumarate/emtricitabine dose. The plasma AUC0-24 was calculated using the trapezoidal rule and compared with historical HIV-negative cisgender adults as geometric mean ratios (GMRs, 90% CI). Secondarily, tenofovir-diphosphate and emtricitabine-triphosphate from PBMCs collected at 0?h and 12?h were reported descriptively as geometric means (90% CI). Clinical trials registration: NCT03270969.Results
Among 15 transwomen (mean age 32?years), geometric mean tenofovir and emtricitabine plasma AUC0-24 were lower compared with controls: tenofovir, 2.10 versus 2.76?mg·h/L, GMR 0.76 (0.65-0.90), P?=?0.01; emtricitabine, 9.15 versus 10.64?mg·h/L, GMR 0.86 (0.75-0.98), P?=?0.07. Tenofovir-diphosphate and emtricitabine-triphosphate concentrations were higher than previously reported in the literature: 167.1 (146.6-190.5) fmol/106 cells and 15.4 (13.8-17.3) pmol/106 cells, respectively.Conclusions
We observed lower plasma tenofovir and emtricitabine concentrations in transwomen compared with historical cisgender adults, yet intracellular tenofovir-diphosphate and emtricitabine-triphosphate concentrations were higher than previously reported in PBMCs. Understanding the differences of PrEP pharmacokinetics in plasma and tissue compartments and the resultant impact on efficacy remains important for transwomen.
SUBMITTER: Cirrincione LR
PROVIDER: S-EPMC7177476 | biostudies-literature | 2020 May
REPOSITORIES: biostudies-literature
Publications
Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy.
The Journal of antimicrobial chemotherapy 20200501 5
<h4>Background</h4>Transwomen have an increased risk of HIV acquisition compared with other adults. Drug-drug interactions between pre-exposure prophylaxis (PrEP) and gender-affirming therapy are cited as a reason for poor PrEP uptake among transwomen. We evaluated plasma tenofovir and emtricitabine pharmacokinetics and their active intracellular anabolites, tenofovir-diphosphate and emtricitabine-triphosphate, in transwomen receiving feminizing hormones.<h4>Methods</h4>We enrolled HIV-negative ...[more]